{"title":"Intermittent treatment with droperidol, a short-acting neuroleptic, increases behavioral dopamine receptor sensitivity.","authors":"R H Belmaker, A Elami, J Bannet","doi":"10.1007/978-3-642-70140-5_24","DOIUrl":null,"url":null,"abstract":"<p><p>Drug holidays have been proposed as a preventive strategy against the development of tardive dyskinesia. Three animal studies in which dopamine receptor hypersensitivity after chronic neuroleptic treatment was used as a model for tardive dyskinesia failed to find any reduction in dopamine receptor hypersensitivity with intermittent, as opposed to continuous, treatment. Since most neuroleptics have a long half-life in vivo, we hypothesized that truly drug-free periods may not have been achieved in previous studies. Droperidol, an ultrashort-acting butyrophenone neuroleptic, was administered to rats for 22 days in twice-daily injections or one injection every 48 hours. At 60 hours after the last dose there was no difference in apomorphine-induced stereotypy between continuously treated and intermittently treated animals. Thus, even totally drug-free periods do not reduce the development of dopamine receptor hypersensitivity.</p>","PeriodicalId":77887,"journal":{"name":"Psychopharmacology. Supplementum","volume":"2 ","pages":"194-9"},"PeriodicalIF":0.0000,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-642-70140-5_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
Abstract
Drug holidays have been proposed as a preventive strategy against the development of tardive dyskinesia. Three animal studies in which dopamine receptor hypersensitivity after chronic neuroleptic treatment was used as a model for tardive dyskinesia failed to find any reduction in dopamine receptor hypersensitivity with intermittent, as opposed to continuous, treatment. Since most neuroleptics have a long half-life in vivo, we hypothesized that truly drug-free periods may not have been achieved in previous studies. Droperidol, an ultrashort-acting butyrophenone neuroleptic, was administered to rats for 22 days in twice-daily injections or one injection every 48 hours. At 60 hours after the last dose there was no difference in apomorphine-induced stereotypy between continuously treated and intermittently treated animals. Thus, even totally drug-free periods do not reduce the development of dopamine receptor hypersensitivity.